Akums Drugs launches Ripasudil-Timolol combination therapy for glaucoma in India

Akums Drugs & Pharmaceuticals has announced the launch of a Ripasudil-Timolol combination therapy for glaucoma treatment in India. This product, approved by the Drug Controller General of India (DCGI), marks a significant step forward in ophthalmic care, with Akums becoming reportedly the first Indian contract development and manufacturing organisation (CDMO) to receive approval for this formulation.

Glaucoma is the second leading cause of irreversible blindness worldwide, with India contributing 23.5 per cent of the global burden. It ranks third among the causes of vision impairment in the country, following cataract and refractive errors. Ocular hypertension, a condition associated with elevated intraocular pressure (IOP), is often seen as a precursor to glaucoma. While not all individuals with ocular hypertension develop glaucoma, regular monitoring and management of IOP are essential to prevent further complications.

The new Ripasudil-Timolol combination therapy provides a dual mechanism of action to control intraocular pressure. Ripasudil enhances aqueous humor outflow through the trabecular meshwork, while Timolol reduces aqueous humor production. This approach delivers more substantial and sustained IOP reduction compared to single-drug treatments.

Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, “This innovation integrates two distinct mechanisms of action to improve glaucoma treatment. By enhancing efficacy and ease of use, we aim to offer a more practical and patient-friendly solution. Our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected. With a patient-first approach and a commitment to Make in India, we continue to develop solutions that are of high quality and aligned with global standards.”

The single combination drop formulation simplifies treatment regimens, which is a significant challenge in glaucoma management due to patient adherence issues. By combining two medications into one product, the therapy offers enhanced convenience and may improve compliance.

“With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial,” added Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals. “This launch marks a significant step in making high-quality and effective treatment more accessible.”

Akums will use its advanced manufacturing facilities to ensure a consistent supply and wide availability of this new therapy. With around 11.9 million people affected by glaucoma in India, the new combination therapy addresses a critical healthcare need by offering an effective solution that simplifies treatment and may improve outcomes.